首页> 外文期刊>Journal of Medicinal Chemistry >Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens
【24h】

Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens

机译:虚拟筛选方法和结构 - 活动关系的调查,探索靶向革兰氏阳性和革兰氏阴性病原体的新型细菌拓扑异构酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Bacterial resistance is increasing rapidly, requiring urgent identification of new antibacterial drugs that are effective against multidrug-resistant pathogens. Novel bacterial topoisomerase inhibitors (NBTIs) provide a new strategy for investigating the well-validated DNA gyrase and topoisomerase IV targets while preventing cross-resistance issues. On this basis, starting from a virtual screening campaign and subsequent structure-based hit optimization guided by X-ray studies, a novel class of piperazine-like NBTIs with outstanding enzymatic activity against Staphylococcus aureus and Escherichia coli DNA gyrase and topoisomerase IV was identified. Notably, compounds (+/-)-33, (+/-)-35, and (+/-)-36 with potent and balanced multitarget enzymatic profiles exhibited excellent efficacy against selected Gram-positive and Gram-negative pathogens, as well as clinically relevant resistant strains. Overall, the new NBTI chemotype described herein, owing to the broad-spectrum antibacterial activity and favorable in vitro safety profile, might serve as a basis for the development of novel treatments against serious infections.
机译:细菌耐药性迅速增加,需要新的抗菌药物是抗多重耐药性病原菌有效迫切鉴定。新的细菌拓扑异构酶抑制剂(NBTIs)用于研究充分验证的DNA促旋酶提供了新的策略和拓扑异构酶IV的目标,同时防止交叉耐药性的问题。在此基础上,从一个虚拟筛选运动和随后的基于结构的命中优化通过X射线研究,一类新的哌嗪等NBTIs与对金黄色葡萄球菌和大肠杆菌DNA促旋酶优秀的酶活性和拓扑异构酶IV的被确定引导开始。值得注意的是,化合物(+/-) - 33,(+/-) - 35和(+/-) - 36具有强效和平衡多目标酶谱显示出极好的功效针对选定的革兰氏阳性和革兰氏阴性病原体,以及作为临床相关的耐药菌株。总的来说,新的NBTI化学型本文所述,由于广谱抗菌活性和体外安全性良好,可以作为对抗严重感染新型治疗药物的开发奠定了基础。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2019年第16期|共28页
  • 作者单位

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Schrodinger 120 West 45th St New York NY 10036 USA;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

    Angelini SpA Angelini RR&

    D Res Regulatory &

    Dev Piazzale Stn SNC S Palomba Pomezia I-00071 Rome Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号